ArticleRSC pharmaceutics2026
Ultrasound-triggered release of an active Wnt signalling agent (6-bromoindirubin-3-oxime) from perfluorocarbon nanodroplets.
Article in RSC pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound-activated perfluorocarbon nanodroplets (NDs) have potential as circulating agents for non-invasive, targeted drug delivery. NDs can be induced to cavitate under focussed ultrasound stimulation, releasing a therapeutic payload. They have been explored widely as a means of drug delivery in oncology but there is less information available on their use in regenerative medicine. Here, we tested the hypothesis that NDs could be fabricated to incorporate an agonist of Wnt signalling, a pathway common to many regenerative tissue-specific processes, and to release it in active form upon ultrasound stimulation. NDs were formed by ultrasonic emulsification of perfluorobutane in the presence of 6-bromoindirubin-3-oxime (BIO) and phospholipids: DSPC and DSPE-PEG2000. The nanodroplet formulation (∼200 nm diameter and 5 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.